Avoid combining GLP-1 agonist with dipeptidyl peptidase 4 (DPP-4) inhibitors as there are no clear-cut data yet available that DPP inhibitors improve outcomes in cardiovascular disease or chronic kidney disease. Here, DPP4 is linked to cardiovascular disorder.